Experience of indinavir/ritonavir 400/100 mg twice-daily highly active antiretroviral therapy-containing regimen in HIV-1-infected patients in Bamako, Mali: the NOGOMA Study

J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):477-9. doi: 10.1097/QAI.0b013e318061b5c3.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antiretroviral Therapy, Highly Active*
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • HIV Protease Inhibitors / administration & dosage
  • HIV Protease Inhibitors / adverse effects
  • HIV Protease Inhibitors / therapeutic use*
  • Humans
  • Indinavir / administration & dosage
  • Indinavir / adverse effects
  • Indinavir / therapeutic use*
  • Male
  • Mali
  • Middle Aged
  • Pilot Projects
  • Ritonavir / administration & dosage
  • Ritonavir / adverse effects
  • Ritonavir / therapeutic use*
  • Treatment Outcome

Substances

  • HIV Protease Inhibitors
  • Indinavir
  • Ritonavir